Read more
9:41 AM · 28 September 2022

Biogen rallies 50% in premarket on Alzheimer drug trial results

Shares of Biogen, a US biotech company, trade around 50% higher in premarket today. Shares rally following results of an Alzheimer drug (Lecanemab) trial that Biogen developed along with Eisai, Japanese pharmaceutical company. Results showed that the pace of cognitive decline in patients who received Lecanemab dropped by 27% over 18 months compared to patients who received placebo. This is massive as it is the first drug to show effectiveness against Alzheimer in a definitive, large-scale trial. While the company noted that some side effects occurred, it also said that they were rarely severe.

Biogen trades around 50% higher in premarket today. Weekly chart. Source: xStation5

23 April 2026, 2:50 PM

Defence sector earnings: Saab, Safran, Lockheed Martin

23 April 2026, 2:27 PM

ServiceNow plunges 13% after earnings 📉Software sell-off kick-off again?

23 April 2026, 2:20 PM

Stock of the Week - Schneider Electric: The Quiet Foundation of the AI and Global Electrification Revolution

23 April 2026, 12:07 PM

Nvidia dominates Big Tech again 🗽 What does the U.S. earnings season show?

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits